oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]
#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment
Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 3 months
Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 3 months
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 18.5 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 19.5 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 21.5 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 22.4 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 34.5 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 47.5 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 50.5 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 51.5 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 56.5 hours
AI improves UK breast-screening detection by about 10% 5 stories in 56.5 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: